|
[1] HONG JT,SON DJ,LEE CK,et al. Interleukin 32,inflammation and cancer[J]. Pharmacol Ther,2017,174:127-137.
|
|
[2] WANG G,WANG Q,HUANG Q,et al. Upregulation of mt SSB by interleukin-6 promotes cell growth through mitochondrial biogenesis-mediated telomerase activation in colorectal cancer[J]. Int J Cancer,2019,144(10):2516-2528.
|
|
[3] ZHONG Z,SANCHEZ-LOPEZ E,KARIN M. Autophagy,inflammation,and immunity:A troika governing cancer and its treatment[J]. Cell,2016,166(2):288-298.
|
|
[4] YANG YM,KIM SY,SEKI E. Inflammation and liver cancer:Molecular mechanisms and therapeutic targets[J]. Semin Liver Dis,2019,39(1):26-42.
|
|
[5] THUN MJ,NAMBOODIRI MM,HEATH CW Jr. Aspirin use and reduced risk of fatal colon cancer[J]. N Engl J Med,1991,325(23):1593-1596.
|
|
[6] SAUER CM,MYRAN DT,COSTENTIN CE,et al. Effect of long term aspirin use on the incidence of prostate cancer:A systematic review and meta-analysis[J]. Crit Rev Oncol Hematol,2018,132:66-75.
|
|
[7] TSOI K,HO J,CHAN F,et al. Long-term use of low-dose aspirin for cancer prevention:A 10-year population cohort study in Hong Kong[J]. Int J Cancer,2019,145(1):267-273.
|
|
[8] QIAO Y,YANG T,GAN Y,et al. Associations between aspirin use and the risk of cancers:A meta-analysis of observational studies[J]. BMC Cancer,2018,18(1):288.
|
|
[9] TANG LP,TANG CW,WANG CH,et al. Inhibiting effects of aspirin on the growth of human hepatocellular carcinoma[J].Chin J Hepatol,2002,10(4):290-293.(in Chinese)汤丽萍，唐承薇，王春晖，等．阿司匹林抑制肝癌生长的试验研究[J]．中华肝脏病杂志，2002,10(4):290-293.
|
|
[10] SIMON TG,MA Y,LUDVIGSSON JF,et al. Association between aspirin use and risk of hepatocellular carcinoma[J].JAMA Oncol,2018,4(12):1683-1690.
|
|
[11] TAO Y,LI Y,LIU X,et al. Nonsteroidal anti-inflammatory drugs,especially aspirin,are linked to lower risk and better survival of hepatocellular carcinoma:A meta-analysis[J].Cancer Manag Res,2018,10:2695-2709.
|
|
[12] SAHASRABUDDHE VV,GUNJA MZ,GRAUBARD BI,et al.Nonsteroidal anti-inflammatory drug use,chronic liver disease,and hepatocellular carcinoma[J]. J Natl Cancer Inst,2012,104(23):1808-1814.
|
|
[13] LEE TY,HSU YC,TSENG HC,et al. Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis B[J]. JAMA Intern Med,2019,179(5):633-640.
|
|
[14] HWANG IC,CHANG J,KIM K,et al. Aspirin use and risk of hepatocellular carcinoma in a national cohort study of Korean adults[J]. Sci Rep,2018,8(1):4968.
|
|
[15] LEE M,CHUNG GE,LEE JH,et al. Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment[J]. Hepatology,2017,66(5):1556-1569.
|
|
[16] CHEN H,CAI W,CHU E,et al. Hepatic cyclooxygenase-2overexpression induced spontaneous hepatocellular carcinoma formation in mice[J]. Oncogene,2017,36(31):4415-4426.
|
|
[17] MARTN-SANZ P,CASADO M,BOSCL. Cyclooxygenase2 in liver dysfunction and carcinogenesis:Facts and perspectives[J]. World J Gastroenterol,2017,23(20):3572-3580.
|
|
[18] YANG G,WANG Y,FENG J,et al. Aspirin suppresses the abnormal lipid metabolism in liver cancer cells via disrupting an NFκB-ACSL1 signaling[J]. Biochem Biophys Res Commun,2017,486(3):827-832.
|
|
[19] LIU YX,FENG JY,SUN MM,et al. Aspirin inhibits the proliferation of hepatoma cells through controlling GLUT1-mediated glucose metabolism[J]. Acta Pharmacol Sin,2019,40(1):122-132.
|
|
[20] YANG G,WANG Y,FENG J,et al. Aspirin suppresses the abnormal lipid metabolism in liver cancer cells via disrupting an NFκB-ACSL1 signaling[J]. Biochem Biophys Res Commun,2017,486(3):827-832.
|
|
[21] RAZA H,JOHN A,BENEDICT S. Acetylsalicylic acid-induced oxidative stress,cell cycle arrest,apoptosis and mitochondrial dysfunction in human hepatoma HepG2 cells[J].Eur J Pharmacol,2011,668(1-2):15-24.
|
|
[22] HUANG Z,FANG W,LIU W,et al. Aspirin induces Beclin-1-dependent autophagy of human hepatocellular carcinoma cell[J]. Eur J Pharmacol,2018,823:58-64.
|
|
[23] GU H,BAI CC,LIU L,et al. Research advances in traditional Chinese medicine regulation of autophagy in treatment of liver cancer[J]. J Clin Hepatol,2019,35(11):2582-2587.(in Chinese)顾欢，白长川，刘柳，等．中医药调控自噬治疗肝癌的研究现状[J]．临床肝胆病杂志，2019,35(11):2582-2587.
|
|
[24] SUN D,LIU H,DAI X,et al. Aspirin disrupts the m TOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via m TORC1 inhibition[J]. Cancer Lett,2017,406:105-115.
|
|
[25] LI JH,WANG Y,XIE XY,et al. Aspirin in combination with TACE in treatment of unresectable HCC:A matched-pairs analysis[J]. Am J Cancer Res,2016,6(9):2109-2116.
|
|
[26] LI S,DAI W,MO W,et al. By inhibiting PFKFB3,aspirin overcomes sorafenib resistance in hepatocellular carcinoma[J].Int J Cancer,2017,141(12):2571-2584.
|
|
[27] XIA H,LEE KW,CHEN J,et al. Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib[J]. Cell Death Discov,2017,3:17058.
|
|
[28] MIAO R,XU X,WANG Z,et al. Synergistic effect of nutlin-3combined with aspirin in hepatocellular carcinoma HepG2 cells through activation of Bcl-2/Bax signaling pathway[J]. Mol Med Rep,2018,17(3):3735-3743.
|
|
[29] ABDLMONSIF DA,SULTAN AS,EL-HADIDY WF,et al. Targeting AMPK,m TOR andβ-catenin by combined metformin and aspirin therapy in HCC:An appraisal in Egyptian HCC patients[J]. Mol Diagn Ther,2018,22(1):115-127.
|
|
[30] XIE ZY,LIU MS,ZHANG C,et al. Aspirin enhances the sensitivity of hepatocellular carcinoma side population cells to doxorubicin via miR-491/ABCG2[J]. Biosci Rep,2018,38(6):BSR20180854.
|
|
[31] SITIA G,AIOLFI R,DI LUCIA P,et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B[J]. Proc Natl Acad Sci U S A,2012,109(32):e2165-e2172.
|
DownLoad: